Sign in
Taking peoplePhase 3

A Trial of Adjunctive Fludrocortisone (50mcg, 100mcg or Placebo) in Critically Ill Patients With Septic Shock Receiving Hydrocortisone, Evaluating Survival and Functional Recovery and the Influence of Transcriptomic Response

Key facts

Who runs it
The George Institute
Where
Australia8 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 3
People taking part
2,200 people, planned
Started
16 Oct 2026
Expected to end
1 Mar 2031
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Fludrocortisone 50 mcg daily
  • Fludrocortisone 100 mcg daily
  • Placebo
Record updated
30 October 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Shock presumed due to infection
  • Treatment with vasopressors to maintain a Systolic Blood Pressure (SBP) >90mmHg or Mean Arterial Pressure (MAP) > 65mmHg, after having received adequate fluid resuscitation (in the opinion of the treating clinician)
  • Plasma lactate concentration >2mmol/L
  • Being treated with hydrocortisone 200mg/day as adjunctive treatment for septic shock
  • Being treated with one of the following:; Invasive Mechanical Ventilation OR; Non-invasive ventilation (CPAP or BiPAP) OR; Oxygen supplementation with an oxygen flow of >10L/min independent of delivery system and an FiO2 of 0.5 or above., OR; Use of Veno-venous ECMO

Who cannot take part

  • Patients unable to receive enteral medications
  • Receiving hydrocortisone (HC) or fludrocortisone (FC) for conditions other than septic shock
  • Prior enrolment in this trial
  • Patients with documented systemic fungal infection at the time of randomisation
  • Patients with documented allergy to fludrocortisone
  • An underlying disease process with a life expectancy of less than 28 days
  • Met all inclusion criteria for more than 12 hours
  • Death is deemed imminent or inevitable by treating ICU specialist
  • Pregnancy (confirmed or suspected)
  • Known or documented objections to research participation

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The FLUDRO-SHOCK trial is a large international randomised controlled double-blinded study aiming to improve treatment for people with septic shock, a life-threatening condition caused by severe infection. Patients with septic shock receive a steroid called hydrocortisone, but it is unclear whether adding another steroid, fludrocortisone, improves their chances of recovery and survival. This study will test two doses of fludrocortisone (50 mcg and 100 mcg) against a placebo to see which works best. It will also explore whether a person's unique immune response, based on their genes, affects how well the treatment works. The trial will involve up to 2,200 critically ill adults in intensive care units across Australia and other countries. Researchers will track survival, organ recovery, and quality of life for up to a year. The goal is to find the most effective and personalised way to use steroids in septic shock, potentially saving lives and improving long-term outcomes.

The 3 groups in the trial

  • Fludrocortisone 50 mcg dailyExisting treatment, for comparison

    The intervention will be fludrocortisone acetate 50 mcg daily, administered orally or via an in situ gastric tube for 7 days or until discharge from ICU, whichever is sooner.

  • Fludrocortisone 100 mcg dailyExisting treatment, for comparison

    The intervention will be fludrocortisone acetate 100 mcg daily, administered orally or via an in situ gastric tube for 7 days or until discharge from ICU, whichever is sooner.

  • PlaceboPlacebo, for comparison

    Matching placebo tablet dosed daily, administered orally or via an in situ gastric tube for 7 days or until discharge from ICU, whichever is sooner.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Adjunctive FLUDrocortisone With tRanscriptOme Evaluation in Septic SHOCK (FLUDRO-SHOCK)
Record updated
30 October 2026